Jon Congleton, Mineralys Therapeutics CEO
January 19, 2023 11:27 AM ESTUpdated 03:40 PM
Financing
Startups

Af­ter hy­per­ten­sion com­peti­tor gets bought, Min­eralys lines up IPO plans

Kyle LaHucik

Senior Reporter

Min­eralys Ther­a­peu­tics has pen­ciled in a $100 mil­lion ini­tial pub­lic of­fer­ing to take its in­ves­ti­ga­tion­al hy­per­ten­sion drug in­to Phase III test­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times